Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma
Authors:
Open Access
- 4 January 2023
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 55 (4) , 867-874
Abstract
Background: The human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2; also known as B7 homolog 7 [B7-H7]) regulates immune responses. However, its immunoregulatory role in upper tract urothelial carcinoma (UTUC) remains unclear. Methods: We evaluated the immunohistochemical expression of HHLA2 and fibroblast activation protein (FAP), which is a marker of cancer-associated fibroblasts, in UTUC tissues from 85 patients who underwent nephroureterectomy. The associations between the expressions of HHLA2 and FAP and clinicopathological characteristics were investigated. Results: The increased expression of HHLA2 in tumor cells (t-HHLA2) was associated with a low histological grade, a negative lymphovascular invasion (LVI), and a low neutrophil-to-lymphocyte ratio, whereas an increased expression of HHLA2 in stromal cells (s-HHLA2) was associated with a high histological grade. No correlation was observed between the expression of t-HHLA2 and s-HHLA2. FAP was expressed only in the stromal cells (s-FAP). Positive s-FAP expression was significantly associated with increased s-HHLA2 expression, higher histological grade, higher pathological T stage, and positive LVI. Higher t-HHLA2 was associated with longer cancer-specific and progression-free survival. In contrast, positive s-FAP was associated with short progression-free survival. Conclusion: These findings suggest that the progression of UTUC may involve increased co-expression of HHLA2 and FAP in the tumor stroma.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K09546)
This publication has 27 references indexed in Scilit:
- A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2Clinical Cancer Research, 2015
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- Cancer-related inflammation and treatment effectivenessThe Lancet Oncology, 2014
- HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell functionProceedings of the National Academy of Sciences, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Cancer-related inflammationNature, 2008
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008